NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free KALA Stock Alerts $6.47 -0.10 (-1.52%) (As of 10:19 AM ET) Add Compare Share Share Today's Range$6.47▼$6.4850-Day Range$6.33▼$7.9952-Week Range$5.10▼$19.35Volume309 shsAverage Volume25,704 shsMarket Capitalization$18.25 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get KALA BIO alerts: Email Address KALA BIO MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside178.2% Upside$18.00 Price TargetShort InterestHealthy0.25% of Float Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($11.28) to ($11.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector249th out of 909 stocksPharmaceutical Preparations Industry103rd out of 423 stocks 3.5 Analyst's Opinion Consensus RatingKALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKALA BIO has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.25% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KALA BIO has recently decreased by 50.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKALA BIO has received a 66.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Glucocorticoids" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for KALA BIO is -1.35. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for KALA BIO this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for KALA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have not sold or bought any company stock.Percentage Held by Insiders13.40% of the stock of KALA BIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.61% of the stock of KALA BIO is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for KALA BIO are expected to decrease in the coming year, from ($11.28) to ($11.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About KALA BIO Stock (NASDAQ:KALA)KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Read More KALA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KALA Stock News HeadlinesApril 22, 2024 | msn.comReba McEntire Uses This Wrinkle-Targeting Moisturizer for Smooth, Glowing Skin at 69April 18, 2024 | msn.comTravis Kelce’s ex Kayla Nicole blasts Taylor Swift’s fans ahead of ‘TTPD’ album release: ‘Everyone has a breaking point’April 24, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 16, 2024 | msn.comNicki Minaj Just Dropped a Sneaker Collection with This Low-Key Brand That Celebs Have Been Wearing for YearsApril 13, 2024 | msn.comWhat can you do with unwanted holy cards and Grandma’s religious statues?April 12, 2024 | msn.comGrace Charis' net worth and biography: Meet the TikTok golf starApril 11, 2024 | msn.comValerie Bertinelli, 63, Shares Stance on Ozempic and Trying to Lose ‘10 Pounds in a Week’April 11, 2024 | msn.com‘Shark Tank’ Star Barbara Corcoran Opens Up About Facelifts and Cosmetic SurgeryApril 24, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 6, 2024 | ca.style.yahoo.comI tried $1,441 worth of products from Sephora — here's what I'm re-buying (and skipping) from the spring saleApril 3, 2024 | msn.com20 famous female celebrities struggling with hair lossApril 2, 2024 | ca.finance.yahoo.com8 Former Child Stars Who've Moved On to 'Typical' (and Impressive!) Day JobsMarch 30, 2024 | msn.comMakeup Artist Trinny Woodall, 60, Shares ‘Foolproof’ Spring Beauty Tips for All AgesMarch 29, 2024 | finanznachrichten.deKALA BIO, Inc.: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | globenewswire.comKALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | ca.style.yahoo.comAmazon's Big Spring Sale is over, but these 40 extended deals are just as good — up to 73% off tech, home & moreMarch 28, 2024 | msn.comRemembering the luminary: Here's how KPAC Sulochana and the golden years of theatre influenced KeralaMarch 21, 2024 | msn.com"All I See Are A Number Of Inaccurate Statements": 11 Celebrities Who Were Accused Of Lying About Their Background And UpbringingMarch 18, 2024 | msn.comGame of Thrones' Nathalie Emmanuel unveils short hair transformationMarch 14, 2024 | msn.com2024 NAACP Image Awards: The Complete Winners ListMarch 12, 2024 | msn.comDenise Austin, 67, Demonstrates ‘Low-Impact’ Burpee in Latest Workout VideoFebruary 26, 2024 | globenewswire.comKALA BIO to Present at TD Cowen 44th Annual Healthcare ConferenceFebruary 23, 2024 | benzinga.comKala Bio Stock (NASDAQ:KALA), Short Interest ReportFebruary 22, 2024 | msn.comFirst trailer for Outlander star Lauren Lyle's shark thrillerFebruary 20, 2024 | msn.comHere Are the Top 6 ‘Bachelor’ Contestants Still in the Running for Joey’s HeartFebruary 13, 2024 | msn.comPatrick and Brittany Mahomes’ History With Travis Kelce’s Ex Kayla Nicole ExplainedFebruary 11, 2024 | msn.comTravis Kelce's Ex Kayla Nicole Parties with Wives of San Francisco 49ers Players Ahead of 2024 Super BowlSee More Headlines Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KALA CUSIPN/A CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees43Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+176.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($17.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-281.02% Return on Assets-65.57% Debt Debt-to-Equity Ratio5.10 Current Ratio6.33 Quick Ratio6.33 Sales & Book Value Annual Sales$3.89 million Price / Sales4.71 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book2.33Miscellaneous Outstanding Shares2,820,000Free Float2,439,000Market Cap$18.33 million OptionableNot Optionable Beta-1.85 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Mark T. Iwicki (Age 58)Chairman & CEO Comp: $1.1MMr. Todd Bazemore (Age 54)President & COO Comp: $783.04kDr. Kim Brazzell Ph.D. (Age 71)Head of R&D and Chief Medical Officer Comp: $750.91kDr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory BoardMs. Mary Reumuth CPA (Age 49)CFO & Treasurer Ms. Jill S. SteierExecutive Director of Investor Relations & Corporate CommunicationsMr. Eric L. Trachtenberg (Age 51)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Comp: $646.56kMr. Vincent Kosewski (Age 61)Senior VP of Manufacturing & Supply Chain Management Mr. Darius Kharabi J.D. (Age 44)M.B.A., Chief Business Officer Dr. Francis S. Mah M.D.Chief Medical AdvisorMore ExecutivesKey CompetitorsFSD PharmaNASDAQ:HUGENeuroSense TherapeuticsNASDAQ:NRSNFlora GrowthNASDAQ:FLGCOrgenesisNASDAQ:ORGSBenitec BiopharmaNASDAQ:BNTCView All CompetitorsInsiders & InstitutionsTower Research Capital LLC TRC Bought 4,357 shares on 2/13/2024Ownership: 0.162%Knights of Columbus Asset Advisors LLCBought 2,417 shares on 1/31/2024Ownership: 0.180%Mark T IwickiSold 4,539 sharesTotal: $30,547.47 ($6.73/share)Eric TrachtenbergSold 1,227 sharesTotal: $8,269.98 ($6.74/share)View All Insider TransactionsView All Institutional Transactions KALA Stock Analysis - Frequently Asked Questions Should I buy or sell KALA BIO stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KALA BIO in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KALA shares. View KALA analyst ratings or view top-rated stocks. What is KALA BIO's stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for KALA BIO's stock. Their KALA share price targets range from $15.00 to $21.00. On average, they predict the company's share price to reach $18.00 in the next year. This suggests a possible upside of 178.2% from the stock's current price. View analysts price targets for KALA or view top-rated stocks among Wall Street analysts. How have KALA shares performed in 2024? KALA BIO's stock was trading at $7.00 at the beginning of 2024. Since then, KALA stock has decreased by 7.6% and is now trading at $6.47. View the best growth stocks for 2024 here. Are investors shorting KALA BIO? KALA BIO saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,000 shares, a decline of 50.4% from the March 15th total of 12,100 shares. Based on an average trading volume of 27,700 shares, the short-interest ratio is currently 0.2 days. Currently, 0.3% of the shares of the stock are short sold. View KALA BIO's Short Interest. When is KALA BIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our KALA earnings forecast. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) released its quarterly earnings data on Friday, March, 29th. The company reported ($3.18) EPS for the quarter. When did KALA BIO's stock split? KALA BIO shares reverse split on the morning of Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What is Mark Iwicki's approval rating as KALA BIO's CEO? 1 employees have rated KALA BIO Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other KALA BIO investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV). When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KALA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
